A Phase Ib, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of Volitinib in Combination With Gefitinib (Iressa) in Patients With Epidermal Growth Factor Receptor-mutated Non-small Cell Lung Cancer Who Have Progressed on Epidermal Growth Factor Receptor Inhibitor Treatment

Trial Profile

A Phase Ib, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of Volitinib in Combination With Gefitinib (Iressa) in Patients With Epidermal Growth Factor Receptor-mutated Non-small Cell Lung Cancer Who Have Progressed on Epidermal Growth Factor Receptor Inhibitor Treatment

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Savolitinib (Primary) ; Gefitinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 31 Jul 2017 According to Chi-Med media release, data from this trial will be presented at a scientific conference in late 2017 or early 2018.
    • 19 Jun 2017 Planned primary completion date changed from 28 Apr 2017 to 28 Nov 2017.
    • 19 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top